Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncologic and Triton BioSystems, two early stage cancer therapy companies, have merged to create Aduro BioTech. Aduro, which is privately held, will be headquartered at the former Oncologic facility in Berkeley, California.
Subscribe to our email newsletter
Aduro will focus on the development of its proprietary and minimally invasive NT and TNT cancer therapies, which use patented iron oxide nanoparticles to target and kill solid tumor cancers.
The nanoparticles are engineered to efficiently generate high levels of heat when exposed to an externally applied magnetic field, and this heat kills tumor cells without the toxicity or collateral damage that result from traditional chemotherapy or radiation treatments.
Stephen Isaacs, CEO of Aduro, said: “We are developing a cancer therapy based on the low toxicity of iron oxide, which is an innocuous material currently used in a variety of medical applications. If successfully developed, the Aduro products will be an exceedingly important addition to the field of solid tumor cancer therapy.”